Pascal Soriot's big experiment: reinventing AstraZeneca

By Ben Hirschler LONDON (Reuters) - AstraZeneca Chief Executive Pascal Soriot is a big believer in science, and the biggest experiment of his career is the reinvention of the drugmaker. Investors are anxious for proof Soriot's prescription will work, since AstraZeneca shares are languishing 28 percent below the 55 pounds offered by Pfizer and earnings are expected to fall in 2016 and 2017.